Newswise — May 8, 2017 – A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
"Virtual reality is potentially a powerful tool for the psychiatric community," comments lead author Jessica L. Maples-Keller, PhD, of University of Georgia. "It allows providers to create computer-generated environments in a controlled setting, which can be used to create a sense of presence and immersion in the feared environment for individuals suffering from anxiety disorders." The review appears as part of a special theme issue of Harvard Review of Psychiatry, focusing on Emerging Technology and Telehealth in Psychiatric Care.
Virtual Reality and Other Technologies Poised to Aid Mental Health Treatment
Dr. Maples-Keller and colleagues review the current state of research on VR technology for psychiatric treatment. So far, research in this area has focused on exposure-based treatment for certain types of anxiety disorders. Studies have evaluated VR applications for progressive exposure to frightening situations in patients with specific phobias—especially fear of flying. Other studies have evaluated the use of VR for treatment of post-traumatic stress disorder in combat veterans.
Virtual reality applications can simulate exposures that would be costly or impractical to re-create in real life, such as airplane flight or combat conditions. It also enables the therapist to control the "dose" and specific aspects of the exposure environment. For example, the patient can "virtually" experience repeated takeoffs and landings without going on an actual flight.
Based on available evidence, VR has significant benefits in these types of anxiety disorders. Studies of flight phobia have reported significant and lasting reductions in flight-related anxiety. Patients report satisfaction with VR-based therapy, and in some cases find it more acceptable than traditional therapy.
Virtual reality has been studied in a wide range of conditions as well, including panic disorder, schizophrenia, acute and chronic pain, addictions (including smoking), and eating disorders. However, research on VR applications has important limitations including small numbers of patients and lack of comparison groups. The authors note that mental health care providers will need specific training before integrating VR approaches into clinical practice.
"With the cost of head-mounted displays coming down and smaller smartphone applications being developed, it is likely that virtual reality applications will proliferate," Dr. Maples-Keller and colleagues conclude. "It will be important that these are treated as tools and therapists are properly trained in their applications." The authors also note the exciting possibility VR provides to conduct methodologically rigorous and controlled clinical research.
The special issue highlights other emerging uses of technology for mental health treatment. These include internet-based approaches to cognitive-behavioral therapy for depression, "telemental" health approaches enabling remote mental health visits, technology-based interventions for substance abuse and accompanying disorders, and standards for evaluating the quality of smartphone applications designed for patients with schizophrenia. Guest Editors Dawn E. Sugarman, PhD, Scott L. Rauch, MD, and Isabelle M. Rosso, PhD of McLean Hospital and Harvard Medical School write, "In this rapidly evolving field, research is striving to leverage new advances in technology as quickly as they emerge."
Article: “The Use of Virtual Reality Technology in the Treatment of Anxiety and Other Psychiatric Disorders” (doi: 10.1097/HRP.0000000000000138)
About the Harvard Review of Psychiatry
The Harvard Review of Psychiatry is the authoritative source for scholarly reviews and perspectives on a diverse range of important topics in psychiatry. Founded by the Harvard Medical School Department of Psychiatry, the journal is peer-reviewed and not industry sponsored. It is the property of Harvard University and is affiliated with all of the Departments of Psychiatry at the Harvard teaching hospitals. Articles encompass all major issues in contemporary psychiatry, including (but not limited to) neuroscience, psychopharmacology, psychotherapy, history of psychiatry, and ethics.
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
MEDIA CONTACTRegister for reporter access to contact details
Harvard Review of Psychiatry